An interesting new paper about the BRCA1 gene was published in the journal Nature last week (see here for a summary of the findings).
An interesting new paper about the BRCA1 gene was published in the journal Nature last week (see here for a summary of the findings). The article is notable because it appears to offer some intriguing possibilities for relatively rapidly bringing even better genomic knowledge into cancer cases. In short, the article is focused on using a version of CRISPR to rapidly test the adverse impact of BRCA1 gene variants (until now the risk from many BRCA1 variants was undefined).
The project appears to have succeeded in providing clarity as to the interpretation of many different BRCA1 variants. In principle, the same methods could be applied to BRCA2, BAP1, TP53, and many of the other variants related to mesothelioma and ovarian cancer that we have been writing about. The testing could thus, in principle, provide more certainty to tell jurors and judges about the impact of a variant on an individual’s cancer risk (and hence provide evidence for a cause other than talc). The testing also could provide insights into mechanisms of action, which also could provide objective evidence that could be helpful to defense efforts.
In our view, the work reflected by this article provides yet another reason for litigators to look even more deeply into the use of genomics, and custom assays.
Download a complimentary copy of our white paper: The Litigator’s Guide to Using Genomics in a Toxic Tort Case
On Wednesday July 8, 2020, Dr. David Schwartz of Innovative Science Solutions presented at the IADC 2020 Virtual Annual Meeting on a panel titled The Use of Genetic Testing in the Courtroom. A complimentary copy of the panel presentation is now available for download. Read more
Dr. David Schwartz of Innovative Science Solutions will be presenting at the IADC 2020 Virtual Annual Meeting on a panel titled The Use of Genetic Testing in the Courtroom. Read more
Plaintiff experts having been asserting for decades that all mesotheliomas must be linked to some asbestos exposure. Indeed, this has led to the erroneous (but widespread) view that mesothelioma is a signature disease, only caused by asbestos exposure. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us